N30 Pharmaceutical appoints Jon Congleton CEO
This article was originally published in Scrip
Executive Summary
Boulder, Colorado-based N30 Pharmaceuticals, a clinical-stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, has named Jon Congleton president and CEO. Mr Congleton will also join the company's board of directors. He joins the firm from Teva Pharmaceuticals, where over 18 years he held positions in general management and global strategic marketing, including senior vice-president of Teva's Central Nervous System Global Franchise, senior VP of the Global Medicines Group, and general manager of Teva Neuroscience.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.